Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Chitogenx Inc C.CHGX

Alternate Symbol(s):  CHNXF

ChitogenX Inc. is a Canada-based emerging orthopedic and sports medicine biologics company. The Company is engaged in the development of therapeutic soft tissue repair technologies to improve the success rate of orthopedic and sports medicine surgeries. The Company’s proprietary biopolymer has been specifically designed to increase the healing rates of occupational and sports related injuries... see more

CSE:CHGX - Post Discussion

Chitogenx Inc > new Vice-President Clinical and Medical Affairs
View:
Post by RockLobster1 on Oct 19, 2020 2:53pm

new Vice-President Clinical and Medical Affairs

MONTREAL , Oct. 19, 2020 /PRNewswire/ - Ortho Regenerative Technologies Inc . (CSE: ORTH) (" Ortho RTI " or the " Company "), an emerging orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today the appointment of Mukesh Ahuja , MBBS, MSc as its new Vice-President Clinical and Medical Affairs, effective November 1 st , 2020.

"It is with great pleasure that we welcome Dr. Ahuja to the Ortho RTI team. With the start of its rotator cuff tear repair clinical program in sight, Ortho RTI has reached a development stage that requires highly specialized expertise and years of experience in managing complex clinical orthopedics research programs. Mukesh brings all of that and more with him", said Claude LeDuc , President and Chief Executive Officer of Ortho RTI. "Ortho will also greatly benefit from Mukesh's track record in supporting the development and commercialization of medical products and technologies as we continue building our Ortho-R product's portfolio of indications in various new musculoskeletal conditions such as tendonitis, ligament and meniscus tears and cartilage lesions as well as a new formulation for OA".

Commenting on his nomination as Ortho RTI's new VP Clinical and Medical Affairs, Mukesh Ahuja said; "I am very excited to be joining Ortho RTI at such a crucial time in its clinical development. There are clear unmet medical needs in the space of soft tissue repair and regenerative medicine that can be addressed with Ortho RTI's technological platform. I look forward to contributing to the advancement of Ortho RTI's clinical program and working with the team in positioning the company as a leader in the orthopedic and sports related injury surgeries".

More about Dr. Mukesh Ahuja

Mukesh Ahuja , MBBS, MSc is a highly qualified, medical executive with fourteen years of US experience as a clinical expert in Orthopedics, managing dozens of orthopedic clinical studies and partnering with surgeons to advance novel research approaches. He has validated expertise in leading and supporting clinical and medical affairs teams within biotechnology companies, medical centers, and clinical research organizations, and has partnered with leading orthopedics companies in exploring novel technologies. Dr. Ahuja has practical knowledge of experimental and clinical research needs to support the development, commercialization and marketing of medical products and technologies. He has a long history of collaboration with physicians, surgeons, scientists/researchers, engineers, sales and marketing executives and other key advisors to identify new markets, and areas of growth and sustainability.

Currently, Dr. Ahuja works at Orthofix Medical, Inc. where he was appointed to develop the clinical strategy for the motion preservation program of spine business franchise. He is also responsible to initiate and lead an IDE trial for a two-level cervical disc replacement device.

Prior to Orthofix, Dr. Ahuja was the Director of Medical and Clinical Affairs for Medacta USA , Inc. At Medacta, he defined and executed a clinical affairs strategy that aligned with the market and commercial needs of company's orthopedic medical devices. He established the clinical department and developed and managed dozens of clinical trials, supporting the needs of the joint reconstruction, spine, and shoulder business units.

He also served as Research Administrator for the world-renowned Department of Orthopedic Surgery at Rush University Medical Center/ Midwest Orthopaedics at Rush . While at Rush , Dr. Ahuja led research programs for Sports Medicine and Spine, consisting of teams responsible for FDA, NIH, and industry trials, as well as investigator-initiated research. He has an extensive clinical research experience in Sports Medicine injuries and treatment products ranging from biologics, stems cells, tissues graft, devices, and drugs.

Dr. Ahuja holds a Masters of Science in Clinical Research from Rush University Medical Center, Chicago , completed a Health Care Management Executive Certificate Program from Loyola University, Chicago , achieved his Certified Principal Investigator (CPI®) certification from ACRP and received a Bachelor of Medicine and Bachelor of Surgery (MBBS) medical degree from Liaquat University of Medical & Health Sciences, Pakistan and a Bachelor of Arts – Political Science and History, University of Sindh, Pakistan .

Mukesh is a member of ACRP and AAHKS and recently joined the regulatory committee of Biologic Association. He also serves as a peer reviewer for OREF research grants committee. Mukesh has contributed to several manuscripts and abstracts published in reputable journals.

Be the first to comment on this post